Business
Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments
Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. and
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities\n Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. and Glenn Morrison, Ph.D. to bolster neuroscience research and clinical development\n\n\nSALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced a deepening of its neuroscience expertise with key hires in human induced pluripotent stem cell (iPSC) biology, translational neuroscience and clinical development. Tim Ahfeldt, Ph.D. will serve as Fellow, Neuroscience; Irit Rappley, Ph.D. will serve as Vice President, Neuroscience and Translational Research; and Glenn Morrison, Ph.D., will serve as Vice President, Clinical Development. In their new roles, Ahfeldt, Rappley and Morrison, respectively, will lead Recursion's efforts to industrialize the use of iPSC-derived neural cell types in high-throughput multi-omics experiments, discover novel biology and central nervous system (CNS)-targeted therapeutics and advance new and existing programs through clinical development. \n\n \n \n \n \n \n \n\n \n\"Diseases of the brain represent one of the most significant areas of unmet medical need. This field has experienced notable failures in developing viable therapeutics and new tools are required to understand foundational neurobiology,\" said Recursion's Senior Vice President of Research, Ron Alfa, M.D., Ph.D. \"Recursion's approach to mapping whole-genome genetic and pharmacological perturbations across neural cell types using custom machine learning solutions allows scientists to explore novel neurobiology to discover and develop potential therapeutics for intractable diseases.\" \nTim Ahfeldt joins Recursion from the Icahn School of Medicine at Mount Sinai, where he was an Assistant Professor in the Departments of Neuroscience and Neurology. Ahfeldt trained with Professor Chad Cowan at the Harvard Stem Cell Institute and has contributed pioneering research to developing human iPSC-derived cells for modeling diseases of the brain, including significant contributions toward understanding the genetics of neurodegenerative diseases such as Parkinson's disease. Ahfeldt will spearhead the ...